Antidepressants Market Analysis

  • Report ID: 4469
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT

Antidepressants Market Segmentation:

Drug Class Segment Analysis

The global antidepressants market is segmented and analyzed for demand and supply by drug class into serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, serotonin antagonist & reuptake inhibitors, and others. Out of these, the selective serotonin reuptake inhibitors segment is projected to significantly grow over the forecast period on the back of growing occurrence of major depressive and anxiety disorders. For instance, anxiety disorders affected 301 million people in 2019, including 58 million children and adolescents. The most commonly prescribed antidepressants are selective serotonin reuptake inhibitors (SSRIs). It is most widely prescribed to treat depression, especially persistent or severe cases, in conjunction with talk therapy such as cognitive behavioral therapy (CBT). Additionally, these drugs have been demonstrated to treat other psychological conditions, which are expected to propel this segment's growth over the forecast period.

Our in-depth analysis of the global market includes the following segments:

      By Drug Class

  • Serotonin-Norepinephrine Reuptake Inhibitors
  • Selective Serotonin Reuptake Inhibitors
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Serotonin Antagonist & Reuptake Inhibitors

      By Indication

  • Major Depressive Disorders
  • Anxiety Disorder
  • Panic Disorder
  • Others

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of antidepressants is estimated at USD 17.41 billion.

The global antidepressants market size was more than USD 16.92 billion in 2025 and is anticipated to grow at a CAGR of over 3.2%, reaching USD 23.18 billion revenue by 2035.

North America antidepressants market will dominate over 46.5% share by 2035, driven by major depressive disorder, rising diagnoses, and healthcare spending.

Key players in the market include AbbVie Inc., Alkermes, Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline plc, Bristol-Myers Squibb Company.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos